Novartis hikes 2019 outlook as gene therapy shines
Novartis has today boosted its full-year targets, as sales of medicines including psoriasis drug Cosentyx and gene therapy Zolgensma helped the Swiss drugmaker surpass analysts' third-quarter expectations.
Business
• 22 Oct 19
